Eine Forschungsstudie, die vergleicht, wie gut verschiedene Dosen des Arzneimittels NN0519-0130 den Blutzucker bei Menschen mit Typ-2-Diabetes senken
Untersuchung der Sicherheit und Wirksamkeit von NNC0519-0130 einmal wöchentlich bei Teilnehmern mit Typ-2-Diabetes – eine Dosisfindungsstudie
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
New South Wales
-
Campbelltown, New South Wales, Australien, 2560
- Campbelltown Hospital
-
Macquarie Park, New South Wales, Australien, 2109
- Macquarie University - Clinical Trials Unit
-
St Leonards, New South Wales, Australien, 2065
- Royal North Shore Hospital
-
Sydney, New South Wales, Australien, 2148
- Western Endocrine Blacktown
-
Sydney, New South Wales, Australien, 2148
- Roger Chih Yu Chen
-
Wollongong, New South Wales, Australien, 2500
- Illawarra Diabetes Service Clinical Trials & Research Unit
-
-
Queensland
-
Birtinya, Queensland, Australien, 4575
- University of Sunshine Coast - Vitality Village
-
Meadowbrook, Queensland, Australien, 4131
- Logan Hospital
-
-
South Australia
-
Oaklands Park, South Australia, Australien, 5046
- Southern Adelaide Diabetes & Endocrine Services
-
-
Victoria
-
Box Hill, Victoria, Australien, 3128
- Eastern Clinical Research Unit Box Hill
-
Camberwell, Victoria, Australien, 3124
- Emeritus Research Melbourne
-
Heidelberg Heights, Victoria, Australien, 3081
- Austin Health, Metabolic Disorders Centre
-
Parkville, Victoria, Australien, 3050
- The Royal Melbourne Hospital
-
Parkville, Victoria, Australien, 3050
- The Royal Melbourne Hospital - Diabetes & Endocrinology Department
-
-
Western Australia
-
Fremantle, Western Australia, Australien, 6160
- Fremantle Hospital
-
-
-
-
-
Bengaluru, Indien, 560054
- MS Ramaiah
-
New Delhi, Indien, 110001
- Lady Hardinge Medical College
-
-
Karnataka
-
Bangalore, Karnataka, Indien, 560092
- Life Care Hospital and Research Centre
-
-
Kerala
-
Kochi, Kerala, Indien, 682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
Madhya Pradesh
-
Indore, Madhya Pradesh, Indien, 452010
- TOTALL Diabetes Hormone Institute
-
-
Maharashtra
-
Mumbai, Maharashtra, Indien, 400012
- Seth GS Medical College & KEM Hospital
-
Pune, Maharashtra, Indien, 411021
- Chellaram Diabetes Institute
-
-
Rajasthan
-
Jaipur, Rajasthan, Indien, 302006
- Diabetes, Thyroid and Endocrine Centre
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Indien, 632004
- Christian Medical College Hospital, Vellore
-
-
Telangana
-
Hyderabad, Telangana, Indien, 500082
- Diabetes Research Center, Hyderabad
-
-
-
-
-
Chiba, Japan, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Soka-shi, Saitama, Japan, 340-0015
- Soka Sugiura Internal Medicine Clinic
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic
-
Tokyo, Japan, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
-
-
-
Québec, Kanada, G1V 4T3
- Diex Recherche Quebec
-
-
British Columbia
-
Kelowna, British Columbia, Kanada, V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Richmond, British Columbia, Kanada, V6V 2L1
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Victoria, British Columbia, Kanada, V8V 4A1
- Cook Street Medical Clinic
-
-
New Brunswick
-
Moncton, New Brunswick, Kanada, E1G 1A7
- G.A. Research Associates Ltd.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 1V7
- Nova Scotia Hlth Halifax
-
-
Ontario
-
Barrie, Ontario, Kanada, L4N 7L3
- Centricity Research Barrie
-
Hamilton, Ontario, Kanada, L8L 5G8
- Wharton Medical Clinic Clinical Trials (Hamilton)
-
Sarnia, Ontario, Kanada, N7T 4X3
- London Road Diagnostic Clinic and Medical Centre
-
Toronto, Ontario, Kanada, M4G 3E8
- Centricity Research Toronto
-
Toronto, Ontario, Kanada, M9V 4B4
- Albion Finch Medical Centre
-
-
Quebec
-
Lévis, Quebec, Kanada, G6W 0M5
- Centricity Research Quebec City
-
Mirabel, Quebec, Kanada, J7J 2K8
- Centricity Research Mirabel
-
Montreal, Quebec, Kanada, H1Y 3H5
- Recherche GCP Research
-
Saint-Laurent, Quebec, Kanada, H4T 1Z9
- Centricity Research Ville St. Laurent VSL
-
-
-
-
Free State
-
Bloemfontein, Free State, Südafrika, 9301
- Josha Research
-
-
Gauteng
-
Johannesburg, Gauteng, Südafrika, 2013
- Wits Bara Clinical Trial Site
-
Midrand, Gauteng, Südafrika, 1685
- Dr A Jacovides and Partners Inc
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Südafrika, 4450
- Dr Pillay's Rooms
-
eMkhomazi, KwaZulu-Natal, Südafrika, 4170
- Dr T Padayachee
-
-
-
-
-
Seoul, Südkorea, 05505
- Asan Medical Center
-
Seoul, Südkorea, 01830
- Nowon Eulji Medical Center, Eulji University
-
Seoul, Südkorea, 03181
- Kangbuk Samsung Hospital
-
Seoul, Südkorea, 02841
- Korea University Anam Hospital
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Südkorea, 13620
- Seoul National University Bundang Hospital
-
-
-
-
California
-
Chula Vista, California, Vereinigte Staaten, 91911
- Velocity Clin Res-Chula Vista
-
Fresno, California, Vereinigte Staaten, 93720
- Valley Research
-
Inglewood, California, Vereinigte Staaten, 90301
- 310 Clinical Research
-
La Mesa, California, Vereinigte Staaten, 91942
- Velocity Clin Res San Diego
-
Lancaster, California, Vereinigte Staaten, 93534
- First Valley Med Grp Lancaster
-
Lomita, California, Vereinigte Staaten, 90717
- Torrance Clin Res Inst, Inc.
-
Los Alamitos, California, Vereinigte Staaten, 90720
- Pacific Clinical Studies
-
Los Angeles, California, Vereinigte Staaten, 90057
- Velocity Clinical Research Westlake
-
Montclair, California, Vereinigte Staaten, 91763
- Catalina Research Institute, LLC
-
San Diego, California, Vereinigte Staaten, 92123
- Artemis Insitute for Clin Res
-
Toluca Lake, California, Vereinigte Staaten, 91602
- Med Partners, Inc.
-
Torrance, California, Vereinigte Staaten, 90505
- UCLA Health Southbay Endocrine
-
Tustin, California, Vereinigte Staaten, 92780
- University Clin Investigators
-
Walnut Creek, California, Vereinigte Staaten, 94598
- Diablo Clinical Research, Inc.
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- University of Colorado Hospital
-
-
Florida
-
Clearwater, Florida, Vereinigte Staaten, 33756
- Innovative Research of W Florida Inc.
-
Clearwater, Florida, Vereinigte Staaten, 33756
- Innovative Research of W FL
-
Miami, Florida, Vereinigte Staaten, 33183
- International Research Associates, LLC_Miami
-
-
Georgia
-
Columbus, Georgia, Vereinigte Staaten, 31904
- Centricity Research
-
-
Idaho
-
Blackfoot, Idaho, Vereinigte Staaten, 83221
- Elite Clinical Trials
-
-
Illinois
-
Peoria, Illinois, Vereinigte Staaten, 61603
- Methodist Medical Center of Illinois
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa
-
-
Maryland
-
Columbia, Maryland, Vereinigte Staaten, 21045
- Centennial Medical Group
-
Oxon Hill, Maryland, Vereinigte Staaten, 20745
- MD Medical Research
-
Rockville, Maryland, Vereinigte Staaten, 20852
- Endo And Metab Cons
-
-
Missouri
-
Springfield, Missouri, Vereinigte Staaten, 65807
- Clinvest Research
-
-
Montana
-
Butte, Montana, Vereinigte Staaten, 59701
- Mercury Str Med Grp, PLLC
-
-
Nebraska
-
Lincoln, Nebraska, Vereinigte Staaten, 68510
- Velocity Clinical Research Lincoln
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89148
- Palm Research Center Inc-Vegas
-
Las Vegas, Nevada, Vereinigte Staaten, 89109
- Excel Clinical Network
-
-
New York
-
Binghamton, New York, Vereinigte Staaten, 13905
- Velocity Clinical Research Binghamton
-
-
North Carolina
-
Greensboro, North Carolina, Vereinigte Staaten, 27408
- PharmQuest Life Sciences LLC
-
Wilmington, North Carolina, Vereinigte Staaten, 28401
- Accellacare Wilmington
-
-
Ohio
-
Canton, Ohio, Vereinigte Staaten, 44718
- Diab & Endo Assoc of Stark Co
-
Cincinnati, Ohio, Vereinigte Staaten, 45242
- Velocity Clin Res_Cincinnati
-
Cincinnati, Ohio, Vereinigte Staaten, 45246
- Velocity Clinical Research Springdale
-
Dayton, Ohio, Vereinigte Staaten, 45439
- Providence Health Partners Ctr
-
Maumee, Ohio, Vereinigte Staaten, 43537
- Advanced Med Res Maumee
-
-
Oregon
-
Grants Pass, Oregon, Vereinigte Staaten, 97527
- Velocity Clin Res Grants Pass
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19114
- Tristar Clin Investigations, PC
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15243
- Preferred Primary Care Physicians Inc.
-
Uniontown, Pennsylvania, Vereinigte Staaten, 15401
- Preferred Primary Care Physicians, Inc.
-
-
Texas
-
Abilene, Texas, Vereinigte Staaten, 79606
- Velocity Clinical Research Abilene
-
Austin, Texas, Vereinigte Staaten, 78759
- Velocity Clin Res Austin
-
Dallas, Texas, Vereinigte Staaten, 75390
- UT Southwestern Med Center
-
Dallas, Texas, Vereinigte Staaten, 75230
- Velocity Clinical Res-Dallas
-
Dallas, Texas, Vereinigte Staaten, 75230
- Zenos Clinical research
-
Forney, Texas, Vereinigte Staaten, 75126
- Care United Research, LLC
-
Houston, Texas, Vereinigte Staaten, 77004
- Endocrine Associates Houston
-
Houston, Texas, Vereinigte Staaten, 77043
- Biopharma Informatic_Houston
-
Irving, Texas, Vereinigte Staaten, 75039
- Tekton Research
-
Lewisville, Texas, Vereinigte Staaten, 75057
- Epic Clinical Research
-
Shavano Park, Texas, Vereinigte Staaten, 78231
- Consano Clinical Research, LLC
-
-
Virginia
-
Burke, Virginia, Vereinigte Staaten, 22015
- Burke Internal Medicine & Research
-
Newport News, Virginia, Vereinigte Staaten, 23606
- TPMG Clinical Research
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Female of non-childbearing potential, or male.
- For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
- Age 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
- Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
- Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
- Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Dosing scheme A (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo-Komparator: Dosing scheme A (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimental: Dosing scheme B (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo-Komparator: Dosing scheme B (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimental: Dosing scheme C (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo-Komparator: Dosing scheme C (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimental: Dosing scheme D (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo-Komparator: Dosing scheme D (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimental: Dosing scheme E (NNC0519-0130)
Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Placebo-Komparator: Dosing scheme E (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Aktiver Komparator: Dosing scheme F (tirzepatide)
Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner. |
Trizepatide will be administered subcutaneously. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Zeitfenster: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as percentage point (%-point) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage point (%-point) |
From baseline (week 0) to end of treatment (week 36)
|
|
Relative change in body weight
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage (%) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Measured as kilograms (kg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Zeitfenster: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as millimoles per liter (mmol/L) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
|
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
Zeitfenster: From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
Measured as percentage point (%-point) |
From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
|
Change in waist circumference
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Measured as centimeter (cm) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Measured as millimeters of mercury (mmHg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Zeitfenster: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Zeitfenster: From baseline (week 0) to end of study (week 40)
|
Measured as number of events |
From baseline (week 0) to end of study (week 40)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NN9541-4945
- U1111-1291-9196 (Andere Kennung: World Health Organization (WHO))
- jRCT2031230704 (Registrierungskennung: JRCT)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .